Anticancer drug development from traditional cytotoxic to targeted therapies: evidence of shorter drug research and development time, and shorter drug lag in Japan.
about
Photo-inducible crosslinked nanoassemblies for pH-controlled drug releaseRecent trends for drug lag in clinical development of oncology drugs in Japan: does the oncology drug lag still exist in Japan?Potential factors correlating to the PMDA's decision to waive Japanese Phase 2 and 3 studies for oncology drugs New Drug Application in Japan.A Computational/Experimental Assessment of Antitumor Activity of Polymer Nanoassemblies for pH-Controlled Drug Delivery to Primary and Metastatic Tumors.
P2860
Anticancer drug development from traditional cytotoxic to targeted therapies: evidence of shorter drug research and development time, and shorter drug lag in Japan.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Anticancer drug development fr ...... and shorter drug lag in Japan.
@en
Anticancer drug development fr ...... and shorter drug lag in Japan.
@nl
type
label
Anticancer drug development fr ...... and shorter drug lag in Japan.
@en
Anticancer drug development fr ...... and shorter drug lag in Japan.
@nl
prefLabel
Anticancer drug development fr ...... and shorter drug lag in Japan.
@en
Anticancer drug development fr ...... and shorter drug lag in Japan.
@nl
P2093
P2860
P1476
Anticancer drug development fr ...... and shorter drug lag in Japan.
@en
P2093
E Kawabata-Shoda
P2860
P304
P356
10.1111/J.1365-2710.2012.01332.X
P577
2012-03-20T00:00:00Z